Table 1.
Pretreatment Characteristics (n=94)
| Characteristic | n(%) |
|---|---|
| Age | |
| <60 | 10 (11%) |
| 60–69 | 52 (55%) |
| ≥70 | 32 (34%) |
| Median (Range) | 67 (46–81) |
| T-Stage | |
| T1c | 57 (61%) |
| T2a | 37 (39%) |
| PSA | |
| ≤4 | 23 (24%) |
| 4–10 | 71 (76%) |
| Median (Range) | 5.93 ng/mL (0.9 – 10.0) |
| Gleason Score (Institutional) | |
| 2–4 | 2 ( 2%) |
| 5 | 9 ( 10%) |
| 6 | 83 (88%) |
| KPS | |
| 80 | 1 (1%) |
| 90 | 25 (27%) |
| 100 | 68 (72%) |
| Volume of Gland by TRUS (grams) | |
| Median (Range) | 33.3 (3.5 – 45.0) |
Abbreviations: PSA=prostate-specific antigen; KPS=Karnofsky performance status; TRUS=transrectal ultrasound